Haematopoietic and immune defects associated with GATA2 mutation

Area of Science:

• Genetics
• Hematology
• Immunology

Background:

• Heterozygous GATA2 mutations cause a multifaceted disorder with immune deficiencies, autoimmunity, and increased malignancy risk.
• Individuals with GATA2 mutations often experience progressive loss of mononuclear cells and elevated FLT3 ligand.
• A 90% risk of clinical complications, including myelodysplastic syndrome (MDS), is observed by age 60.

Purpose of the Study:

• To summarize the clinical manifestations and management of GATA2-related disorders.
• To highlight the genetic basis and pathogenic mechanisms of GATA2 mutations.
• To inform on the long-term prognosis and therapeutic strategies for GATA2 mutation carriers.

Main Methods:

• Review of literature on GATA2 mutations and associated clinical phenotypes.
• Analysis of genetic mutation types and their distribution within the GATA2 gene.
• Description of current management strategies and treatment outcomes.

Main Results:

• GATA2 mutations, including various types, are concentrated in the zinc finger domains and cause haplo-insufficiency.
• Clinical complications include infections, pulmonary dysfunction, autoimmunity, lymphoedema, and hematologic malignancies.
• High risk of MDS/acute myeloid leukemia and premature death from associated complications.

Conclusions:

• GATA2 mutations result in significant immune compromise and a high predisposition to hematologic malignancies.
• Management requires genetic counseling, infection prevention, cancer surveillance, and hematopoietic monitoring.
• Hematopoietic stem cell transplantation is a key therapeutic option for life-threatening complications like MDS.